```
     FILE 'HCAPLUS' ENTERED AT 13:20:40 ON 27 JUL 2007
L1         80214 S MONOCLONAL(W)ANTIBODY
L2          1760 S EPIDERMOID(W)(CANCER OR CARCINOMA OR TUMOR)
L3         69702 S COMPLEMENT
L4          4678 S BETA-GLUCAN
L5        366038 S VISCOSITY

     FILE 'STNGUIDE' ENTERED AT 13:20:45 ON 27 JUL 2007

     FILE 'HCAPLUS' ENTERED AT 13:21:50 ON 27 JUL 2007
L6           123 S L1 AND L2
L7             2 S L3 AND L6
L8           479 S L4 AND L5
L9           114 S L6 AND (PY<2001 OR AY<2001 OR PRY<2001)
L10            2 S L7 AND (PY<2001 OR AY<2001 OR PRY<2001)
L11          260 S L8 AND (PY<2001 OR AY<2001 OR PRY<2001)

     FILE 'STNGUIDE' ENTERED AT 13:22:03 ON 27 JUL 2007

     FILE 'HCAPLUS' ENTERED AT 13:22:17 ON 27 JUL 2007

     FILE 'STNGUIDE' ENTERED AT 13:22:18 ON 27 JUL 2007

     FILE 'HCAPLUS' ENTERED AT 13:24:16 ON 27 JUL 2007
L12        25311 S IMMUNOSTIMULA?
L13       817924 S (CANCER OR TUMOR OR NEOPLAS? OR ANTICANCER OR ANTITUMOR OR AN
L14            3 S L11 AND L12
L15            3 S L11 AND L13
L16            0 S L11 AND L12 AND L13
```

```
=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.42       0.42

FILE 'HCAPLUS' ENTERED AT 13:20:40 ON 27 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Jul 2007  VOL 147 ISS 6
FILE LAST UPDATED: 26 Jul 2007  (20070726/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s monoclonal(w)antibody

        147752 MONOCLONAL
        314272 ANTIBODY
L1       80214 MONOCLONAL(W)ANTIBODY

=> s epidermoid(w)(cancer or carcinoma or tumor)

          2355 EPIDERMOID
        323136 CANCER
        163775 CARCINOMA
        415514 TUMOR
L2        1760 EPIDERMOID(W)(CANCER OR CARCINOMA OR TUMOR)

=> s complement

L3       69702 COMPLEMENT

=> s beta-glucan

       1467284 BETA
         15132 GLUCAN
L4        4678 BETA-GLUCAN
                (BETA(W)GLUCAN)

=> s viscosity

L5      366038 VISCOSITY

=> file stnguide

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.60       3.02
```

```
FILE 'STNGUIDE' ENTERED AT 13:20:45 ON 27 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 20, 2007 (20070720/UP).

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.12       3.14

FILE 'HCAPLUS' ENTERED AT 13:21:50 ON 27 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Jul 2007  VOL 147 ISS 6
FILE LAST UPDATED: 26 Jul 2007  (20070726/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l1 and l2

L6          123 L1 AND L2

=> s l3 and l6

L7            2 L3 AND L6

=> s l4 and l5

L8          479 L4 AND L5

=> s l6 and (PY<2001 or AY<2001 or PRY<2001)

      20934243 PY<2001
       3907932 AY<2001
       3386907 PRY<2001
L9          114 L6 AND (PY<2001 OR AY<2001 OR PRY<2001)

=> s l7 and (PY<2001 or AY<2001 or PRY<2001)

      20934243 PY<2001
       3907932 AY<2001
       3386907 PRY<2001
L10           2 L7 AND (PY<2001 OR AY<2001 OR PRY<2001)

=> s l8 and (PY<2001 or AY<2001 or PRY<2001)
```

```
      20934243 PY<2001
       3907932 AY<2001
       3386907 PRY<2001
L11         260 L8 AND (PY<2001 OR AY<2001 OR PRY<2001)

=> file stnguide

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.60       5.74

FILE 'STNGUIDE' ENTERED AT 13:22:03 ON 27 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 20, 2007 (20070720/UP).

=> d l7 1-2 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L7   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Antibodies and autoantigen and methods for diagnosis and treatment of
     insulin-dependent diabetes mellitus
AB   A monoclonal antibody (MAb) is provided which is
     reactive with β cell autoantigen on human pancreatic β cells
     having a mol. weight of .apprx.64 kDa and associated with the onset of
     insulin-dependent diabetes mellitus (IDDM). The MAb is useful for
     diagnosis, treatment, and prevention of IDDM. The β cell autoantigen
     is useful for diagnosis of early onset of IDDM. Also disclosed are
     immunotherapeutic methods employing anti-id MAbs and the β cell
     autoantigen. These methods are employed for inhibiting the binding of
     islet cell autoantibodies to pancreatic islet cells, and for removing
     islet cell autoantibodies and lymphocytes reactive with β cell
     autoantigen from the peripheral circulation of a subject. A vaccine to
     prevent IDDM comprises the MAb or fragments of the MAb for production of
     anti-id antibodies reactive with autoantibodies. A cDNA library
     comprising cDNA sequences coding for the autoantigen and the recombinant
     cDNA are also claimed. Hybridoma ATCC Number HB 10502 producing DM MAb to
     β cell autoantigen, was produced by fusing splenocytes from a male
     spontaneously diabetic nonobese mouse with myeloma cells from cell line
     HL1-653, cloning, selection, etc. It was unexpectedly found that cell
     lines not derived from pancreatic tissue in culture produced substantial
     quantities of β cell autoantigen; the 64-kDa autoantigen was purified
     from HEp2 cells. A cDNA library was constructed from HEp2 cells and the
     autoantigen cDNA was cloned and expressed in Escherichia coli.
AN   1992:406018  HCAPLUS <<LOGINID::20070727>>
DN   117:6018
TI   Antibodies and autoantigen and methods for diagnosis and treatment of
     insulin-dependent diabetes mellitus
IN   Lin, Hun Chi; Thai, Toha; Lei, Shau Ping
PA   Trigen Inc., USA
SO   PCT Int. Appl., 78 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   WO 9206105           A1    19920416    WO 1991-US7052           19910925
         W:  AU, CA, JP, NO
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
```

	AU 9188647	A	19920428	AU 1991-88647	19910925
PRAI	US 1990-591608	A	19901002		
	WO 1991-US7052	A	19910925		

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Monoclonal antibodies against the receptor for epidermal growth factor as potential anticancer agents
AB Epidermal growth factor (EGF) stimulates the proliferation of fibroblasts and most epithelial cell types, whereas it profoundly inhibits the growth of A431 epidermoid carcinoma cells. The growth of 8 EGF receptor-bearing human tumor cell lines was measured following the addition of EGF or monoclonal anti-EGF receptor antibody 528 IgG2a (which blocks EGF binding). Epidermoid carcinoma cell lines from lung (T222), skin (T423), and vulva (A431) were growth-inhibited by both EGF and 528 IgG. Proliferation of the other five human tumor cell lines tested was not blocked by either EGF or 528 IgG. Xenografts of the three cell lines inhibited by EGF and 528 IgG in culture were inhibited by 528 IgG treatment in vivo, whereas the other five tumors were unaffected. Differences in the number of EGF receptors expressed on the cell surface did not account for the inhibition of selected receptor-bearing tumor cells. Monoclonal antibody 225 IgG1 also prevented proliferation of A431 cells in culture and xenografts. Screening for complement-mediated and cellular mechanisms of cytotoxicity demonstrated cytolytic effects of macrophages upon A431 cells in the presence of 528 IgG2a, but no immune mechanism could be found to explain the antitumor on 225 IgG1. Thus, the antiproliferative activity may be related to direct effects upon the receptor. Thus, immunotherapy of xenografts with anti-EGF receptor antibody is effective against a subset of receptor-bearing cells, which are also, in all cases, inhibited in vitro.
AN 1988:508679 HCAPLUS <<LOGINID::20070727>>
DN 109:108679
TI Monoclonal antibodies against the receptor for epidermal growth factor as potential anticancer agents
AU Mendelsohn, J.; Masui, H.; Sunada, H.; MacLeod, C.
CS Mem. Sloan Kettering Cancer Cent., New York, NY, 10021, USA
SO UCLA Symposia on Molecular and Cellular Biology, New Series (1988), 56(Cell. Mol. Biol. Tumors Potential Clin. Appl.), 307-12
CODEN: USMBD6; ISSN: 0735-9543
DT Journal
LA English

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	14.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.56

FILE 'HCAPLUS' ENTERED AT 13:24:16 ON 27 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jul 2007 VOL 147 ISS 6
FILE LAST UPDATED: 26 Jul 2007 (20070726/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s immunostimula?

L12 25311 IMMUNOSTIMULA?

=> s (cancer or tumor or neoplas? or anticancer or antitumor or antineoplas?)

323136 CANCER
415514 TUMOR
503093 NEOPLAS?
41696 ANTICANCER
230497 ANTITUMOR
11400 ANTINEOPLAS?
L13 817924 (CANCER OR TUMOR OR NEOPLAS? OR ANTICANCER OR ANTITUMOR OR ANTINEOPLAS?)

=> s l11 and l12

L14 3 L11 AND L12

=> s l11 and l13

L15 3 L11 AND L13

=> s l11 and l12 and l13

L16 0 L11 AND L12 AND L13

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	16.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.56

FILE 'STNGUIDE' ENTERED AT 13:24:23 ON 27 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 20, 2007 (20070720/UP).

=> d l14 1-3 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L14 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Composition of β -glucan and silver-containing component and use as antimicrobial and immunostimulating agent

in wound healing

L14 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Development of a water-soluble carboxymethyl-β-(1→3)-glucan derived from Saccharomyces cerevisiae

L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Method for producing soluble glucans

=> d l14 1-3 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L14 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Composition of β -glucan and silver-containing component and use as antimicrobial and immunostimulating agent in wound healing
AB The present invention provides a medical composition comprising an antimicrobially effective and immunostimulating amount of a combination of a β -glucan component and a silver-containing component. The medical composition may be adapted for use topically or incorporated with a mesh material which may be further adapted for use as a wound dressing or as a surgical mesh. Methods for manufacturing the medical compns. described herein are also provided. The invention further provides methods for treating tissue damaged by wound or burn, and methods for treating or repairing tissue at a surgical site.
AN 2004:18739 HCAPLUS <<LOGINID::20070727>>
DN 140:65167
TI Composition of β -glucan and silver-containing component and use as antimicrobial and immunostimulating agent in wound healing
IN Klein, Barbara K.; Katzner, Leo D.
PA USA
SO U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 538,655, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004005364	A1	20040108	US 2003-460760	20030612 <--
	US 2006240083	A1	20061026	US 2006-428929	20060706 <--
PRAI	US 2000-538655	B2	20000330 <--		
	US 2003-460760	A3	20030612		

L14 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Development of a water-soluble carboxymethyl-β-(1→3)-glucan derived from Saccharomyces cerevisiae
AB The report describes a method for the solubilization of micro-particulate β-(1→3)-glucan. Insol. glucan is suspended in sodium hydroxide and partially carboxymethylated at 65°. The resulting water-soluble product is called CMG. The solubility is ≤98%. The substituted degree is about 0.2-0.3. Mol. weight and intrinsic viscosity were determined by gel permeation chromatog. and viscometer. 13C-NMR spectroscopy confirmed the β-(1→3) interchain linkage. In solution CMG self-assocs. partly in a triple helix. The ability to prepare an immunol. active, water-soluble β-(1→3)-glucan preparation will greatly enhance the utility of this class of compds.
AN 1999:577989 HCAPLUS <<LOGINID::20070727>>
DN 132:105046
TI Development of a water-soluble carboxymethyl-β-(1→3)-glucan

derived from Saccharomyces cerevisiae
AU Ding, Xiao Lin; Wang, Miao
CS School of Food Science and Technology, Wuxi University of Light Industry, Wuxi, Peop. Rep. China
SO Food for Health in the Pacific Rim, International Conference of Food Science and Technology, 3rd, Davis, Calif., Oct. 19-23, 1997 (1999), Meeting Date 1997, 412-419. Editor(s): Whitaker, John R. Publisher: Food & Nutrition Press, Trumbull, Conn.
CODEN: 68BQAF
DT Conference
LA English
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Method for producing soluble glucans
AB Title glucans, acceptable for pharmaceutical uses, are yeast-based and neutral, and are obtained by contacting glucan particles with an acid solution, followed by contacting the acid-treated particles with an alkali solution The alkali-soluble glucan is then separated from insol. particles and aggregates, and neutralized. Yeasts for the glucan particle production comprise Saccharomyces cerevisiae strain R4 (NRRLY-15903). Thus, 100 g glucan particles, after suspended in 3 L 90% formic acid at room temperature for
1 h, was heated to 80, sirred until a sudden drop in viscosity was observed, and combined with 9 L EtOH to give a precipitate which, after collected, was dissolved in 0.4 M NaOH solution, and centrifuged. The supernatant was concentrated, dialyzed with 10 volume of water, concentrated, equilibrated in sterile isotonic saline by dialysis, and assayed showing affinity to β -glucan receptor of monocytes.
AN 1991:209485 HCAPLUS <<LOGINID::20070727>>
DN 114:209485
TI Method for producing soluble glucans
IN Jamas, Spiros; Easson, D. Davidson, Jr.; Ostroff, Gary R.
PA Alpha Beta Technology, Inc., USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9103495	A1	19910321	WO 1990-US5041	19900906 <--
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 2066172	A1	19910309	CA 1990-2066172	19900906 <--
	AU 9064411	A	19910408	AU 1990-64411	19900906 <--
	AU 650626	B2	19940630		
	EP 490995	A1	19920624	EP 1990-914588	19900906 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 05503952	T	19930624	JP 1990-513727	19900906 <--
	US 5322841	A	19940621	US 1992-970547	19921102 <--
	US 5488040	A	19960130	US 1993-60418	19930511 <--
	US 5849720	A	19981215	US 1995-400488	19950308 <--
	US 5633369	A	19970527	US 1995-464528	19950605 <--
	US 5663324	A	19970902	US 1995-464527	19950605 <--
PRAI	US 1989-404738	A2	19890908 <--		
	WO 1990-US5041	A	19900906 <--		
	US 1992-838288	A2	19920305 <--		
	US 1992-855578	B2	19920323 <--		
	US 1992-934015	A2	19920821 <--		
	US 1992-970547	A3	19921102 <--		

US 1994-257062 B1 19940609 <--
US 1995-432303 A1 19950502 <--

=> d l15 1-3 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The potential of hull-less barley
AB A review with 124 refs. Hull-less barley (HB) has been investigated in many countries for use in feed, food, and industry since the publication of the last review in 1986. Literature published since 1990 on various aspects of HB utilization, other than in monogastric feeds, has been reviewed. Several HB cultivars containing low or high β - glucan, low or high extract viscosity, and waxy (0-5% amylose) or normal starch are now available. Interest in HB utilization in the food industry developed largely due to its high β - glucan content, particularly in the waxy cultivars. .beta .-Glucan is a major component of soluble fiber implicated in hypocholesterolemia, hypoglycemia, and in reducing incidence of chemical induced colon cancer in exptl. animals. However, large-scale clin. trials using human subjects are needed to corroborate these effects. The zero amylose HB starch had low syneresis or a high freeze-thaw stability suitable for use in frozen foods. Single- or double-modified waxy HB starch may replace corn starch in some food applications, and cationized HB starch can replace corn and potato starches in the pulp and paper industry. HB may be milled using conventional wheat milling equipment to yield bran and flour for multiple food uses. Hull-less barley may also be used as feed stock for fuel alc. production, for the preparation of food malt with low or high enzyme activities, and for brewer's and distiller's malts.
AN 1999:636767 HCAPLUS <<LOGINID::20070727>>
DN 131:335948
TI The potential of hull-less barley
AU Bhatty, R. S.
CS Crop Development Centre, Department of Plant Sciences, University of Saskatchewan, Saskatoon, SK, S7N 5A8, Can.
SO Cereal Chemistry (1999), 76(5), 589-599
CODEN: CECHAF; ISSN: 0009-0352
PB American Association of Cereal Chemists
DT Journal; General Review
LA English
RE.CNT 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Studies on the conformation and conformational variations of the β-D-glucan produced by Sclerotinia sclerotiorum SS-001
AB The β-D-Glucan, with potential antitumor activity, produced by Sclerotinia sclerotiorum SS-001, was investigated on its solution behaviors, conformation and conformational change. By studying the effects of ionic strength and pH value on the intrinsic viscosity , the authors found that the solution behavior is relatively stable. Nevertheless, when the pH value of the solution surpassed 12.36, the value of intrinsic viscosity would decrease rapidly. By TEM we found this change of solution behavior to be due to the conformational variations of the mols.
AN 1996:504750 HCAPLUS <<LOGINID::20070727>>
DN 125:190122
TI Studies on the conformation and conformational variations of the β-D-glucan produced by Sclerotinia sclerotiorum SS-001

AU Yu, Xianchao; Wang, Derun; Liu, Yi; Yu, Ao; Liu, Rulin; Sun, Bangfu; Ru, Xiangbin
CS Central Lab., Nankai Univ., Tianjin, 300071, Peop. Rep. China
SO Gaofenzi Xuebao (1996), (3), 296-303
CODEN: GAXUE9; ISSN: 1000-3304
PB Kexue
DT Journal
LA Chinese

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Physicochemical properties of a β -glucan from Sclerotinia sclerotiorum
AB Sclerotan (SSG) was an extracellular polysaccharide from Sclerotinia sclerotiorum by submerged fermentation It had potential immunomodulating and antitumor activity. The SSG was a glucan composed of β-linked D-glucoses. It was hard to dissolve in water under normal condition, but its aqueous solution had fine rheol. properties. Its intrinsic viscosity [η] hardly changed with ionic strength. Change of its [η] value was not remarkable between pH 1.88-12.36. Nevertheless, when the pH came to 13.32, the [η] value decreased rapidly due to change of mols. conformation. Effect of temperature ≤90°C and heat treatment on apparent viscosity of SSG solution was minor.
AN 1995:585366 HCAPLUS <<LOGINID::20070727>>
DN 123:28178
TI Physicochemical properties of a β -glucan from Sclerotinia sclerotiorum
AU Liu, Rulin; Wang, Derun; Yu, Xianchao
CS Dep. Microbiol., Nankai Univ., Tianjin, 300071, Peop. Rep. China
SO Weishengwu Xuebao (1995), 35(2), 103-8
CODEN: WSHPA8; ISSN: 0001-6209
PB Kexue
DT Journal
LA Chinese